Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Clin Cancer Res. 2019 Jun 21;25(19):5984–5996. doi: 10.1158/1078-0432.CCR-18-3399

Figure 4. FGTI-2734 inhibits in vivo growth of mutant KRAS-dependent (MiaPaCa2, L3.6pl, Calu6), but not mutant KRAS-independent (A549, H460 and DLD1), tumors and inhibits growth of xenografts from pancreatic cancer patients.

Figure 4.

The growth of human tumors following injection of MiaPaCa2, L3.6pl, Calu6 (left panels), A549, H460, and DLD1 (middle panels) cancer cells into SCID-bg mice was determined as described in the Methods. Mice were treated with vehicle (red) and 100 mg/kg body weight FGTI-2734 (green). Right panels show effects of vehicle (red) and 100 mg/kg body weight FGTI-2734 (green) on growth of patient-derived xenograft (PDXs) tumors from patients with pancreatic cancer. Data are presented as means ± standard error. Asterisks indicate statistical significance (p < 0.05).